Shionogi Invests in Restore Vision's Gene Therapy for Retinal Blindness Through First CVC Deal
Key Insights
Shionogi & Co. (search) has made its first Corporate Venture Capital investment in Tokyo-based startup Restore Vision Inc. (search), which is developing visual restoration gene therapy (search) for retinal disorders (search).
The startup's innovative technology utilizes a unique functional gene coding "Chimeric Rhodopsin (search)," a protein-based optical sensor designed to restore vision in patients with blindness (search) caused by retinal disorders (search).
This investment represents Shionogi's strategic expansion beyond pharmaceuticals through its CVC platform established in April 2025 to explore next-generation growth opportunities in new markets and technology areas.
Shionogi & Co. (search), Ltd. announced on April 15, 2026, that it has made an equity investment in Restore Vision Inc. (search), a Tokyo-based startup developing innovative gene therapy technologies for ophthalmology. This marks Shionogi's inaugural investment through its Corporate Venture Capital (CVC) activities, signaling the pharmaceutical company's strategic expansion into emerging healthcare technologies.
Strategic CVC Initiative Targets Healthcare Innovation
Shionogi established its Corporate Venture Capital platform in April 2025 to explore next-generation growth opportunities across new markets and technology areas. The CVC targets a broad range of investment areas beyond traditional pharmaceuticals, including technology, infrastructure, and resources. Through these activities, Shionogi seeks to create new value that contributes to addressing social challenges and advancing healthcare.
The pharmaceutical company aims to build early-stage partnerships with startup companies that possess innovative technologies and business ideas, supporting them by leveraging Shionogi's research and development capabilities, business experience, and network—thereby fostering relationships that contribute to mutual growth.
Chimeric Rhodopsin Technology Addresses Unmet Medical Need
Restore Vision Inc. (search) is developing visual restoration gene therapy (search) using its unique functional gene coding "Chimeric Rhodopsin (search)," which functions as a protein-based optical sensor. The company's technology is expected to contribute to addressing social challenges associated with blindness (search) caused by retinal disorders (search), for which effective preventive or curative treatments have not yet been established.
The startup's approach targets the significant burden experienced by patients with retinal disorder-related blindness (search) and the challenges faced by those around them. Founded on November 14, 2016, Restore Vision operates from Toranomon Hills Business Tower in Tokyo under the leadership of CEO Yusaku Katada and COO Hikaru Miyazaki.
Partnership Potential in Regenerative Medicine
The investment aligns with Restore Vision's focus on research and development of regenerative medicine products. The collaboration between Shionogi's established pharmaceutical expertise and Restore Vision's innovative gene therapy platform represents a strategic approach to addressing unmet medical needs in ophthalmology.
This partnership demonstrates Shionogi's commitment to expanding its therapeutic reach beyond its traditional pharmaceutical portfolio while supporting breakthrough technologies that could transform treatment options for patients with vision-threatening retinal disorders (search).